Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

About the Study

This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).

This study is no longer enrolling people.

What the Study Entails

The study involves two group:

Group 1:

Participants receive pembrolizumab on Day 1 of each cycle, which lasts 6 weeks, for up to 18 cycles (about 2 years) injected into the vein.

Group 2:

Participants receive a combination chemotherapy of carboplatin and paclitaxel on Day 1 of each 3-week cycle for 6 cycles (about 4 months) injected into the vein.

Study Sites

Arizona

• Phoenix
  HonorHealth-USOR HonorHealth (Site 8000)
  Contact: Study Coordinator   (602) 406-7730

California

• La Jolla
  Moores Cancer Center (Site 0037)
  Contact: Study Coordinator   (858) 822-6100
• Riverside
  Kaiser Permanente Riverside Medical Center (Site 0045)
  Contact: Study Coordinator   (800) 398-3996

Connecticut

• New Haven
  Smilow Cancer Center at Yale-New Haven (Site 0013)
  Contact: Study Coordinator   (203) 688-4242

Florida

• Miami Beach
  Mount Sinai Cancer Center (Site 0018)
  Contact: Study Coordinator   (305) 674-2625
• Sarasota 
  Sarasota Memorial Hospital (Site 0005)
  Contact: Study Coordinator (941) 917-2225

Georgia

• Atlanta
  Northside Hospital (Site 0017)
  Contact: Study Coordinator   (404) 851-8000
• Newman
  Southeastern Regional Medical Center
  Contact: Study Coordinator   (770) 400-6000

Illinois

• Zion
  Midwestern Regional Medical Center, Inc (Site 0003)
  Contact: Study Coordinator (847) 731-1777

Indiana

• Indianapolis
  St. Vincent Hospital and Health Care Center, Inc (Site 0006)
  Contact: Study Coordinator   (317) 415-6740

Kentucky

• Lexington
  Baptist Health Lexington (Site 0042)
  Contact: Study Coordinator   (502) 802-6829

Maryland

• Rockville
  Maryland Oncology Hematology (Site 8002)
  Contact: Study Coordinator   (301) 933-3216

Massachusetts

• Worcester
  University of Massachusetts Medical School - Division of Gynecologic Oncology (Site 0008)
  Contact: Study Coordinator   (508) 856-3216

Michigan

• Detroit
  Karmanos Cancer Institute (Site 0029)
  Contact: Study Coordinator   (800) 526-6266

Mississippi

• Jackson
  St. Dominic’s Hospital (Site 0024)
  Contact: Study Coordinator   (601) 200-4974

New Jersey

• Hackensack
  John Theurer Cancer Center at Hackensack University Medical Center (Site 0026)
  Contact: Study Coordinator   (551) 996-5855

New York

• New York
  The Blavatnik Family - Chelsea Medical Center at Mount Sinai (Site 0023)
  Contact: Study Coordinator   (212) 694-6000
• New York
  Laura and Isaac Perlmutter Cancer Center at NYU Langone (Site 0016)
  Contact: Study Coordinator   (212) 731-6455
• New York
  Icahn School of Medicine at Mount Sinai (Site 0052)
  Contact: Study Coordinator   (212) 241-6500
• New York
  Memorial Sloan Kettering Cancer Center (Site 0009)
  Contact: Study Coordinator   (646) 888-4224

North Carolina

• Pinehurst
  FirstHealth CLinical Trials (Site 0050)
  Contact: Study Coordinator   (910) 715-2200

North Dakota

• Bismark
  Sanford Medical Center (Site 0054)
  Contact: Study Coordinator   (605) 376-4905
• Fargo
  Sanford Fargo Medical Center - Roger Maris Cancer Center (Site 0055)
  Contact: Study Coordinator   (605) 376-4905

Ohio

• Cincinnati
  University of Cincinnati Medical Center - University of Cincinnati Cancer Center (Site 0039)
  Contact: Study Coordinator   (513)584-7698
• Columbus
  The James Cancer Hospital and Solove Research Institute at the Ohio State University Comprehensive Center
  Contact: Study Coordinator   (614) 293-3873

Oregon

• Portland
  Providence Portland Medical Center (Site 0031)
  Contact: Study Coordinator   (503) 215-2614

Pennsylvania

• Philadelphia
  Sidney Kimmel Cancer Center - Jefferson Health (Site 0053)
  Contact: Study Coordinator   (215) 481-4000
• Pittsburgh
  University of Pittsburgh Medical Center Magee-Womens Hospital (Site 0034)
  Contact: Study Coordinator   (412) 642-5411
• Pittsburgh
  AHN West Penn Hospital (Site 0011)
  Contact: Study Coordinator   (412) 330-6151
• Willow Grove
  Asplundh Cancer Pavilion (Site 0014)
  Contact: Study Coordinator   (215) 481-4000

South Dakota

• Sioux Falls
  Sanford Cancer Center - Gynecologic Oncology (Site 0002)
  Contact: Study Coordinator   (605) 312-3250

Texas

• Austin
  Texas Oncology - Austin-USOR Texas Oncology (Site 8003)
  Contact: Study Coordinator   (512) 421-4250
• Dallas
  Texas Oncology - Dallas-USOR Texas Oncology (Site 8005)
  Contact: Study Coordinator   (214)370-1000
• Tyler
  Texas Oncology - Tyler-USOR Texas Oncology (Site 8004)
  Contact: Study Coordinator   (903) 579-9800

Virginia

• Richmond
  VCU Health Adult Outpatient Pavillion (Site 0022)
  Contact: Study Coordinator   (804) 828-9080